

## 【Symposium 5-4】

### **Latest developments of IgA nephropathy clinical trials**

Fan-Chi Chang

Division of Nephrology, National Taiwan University Hospital

IgA nephropathy (IgAN), the most common primary glomerular disease worldwide, has historically been treated with general immunosuppressive therapies and optimized supportive measures. Despite advances in understanding the disease's pathophysiology, treatment options have remained limited. However, recent breakthroughs in clinical trials are reshaping the therapeutic landscape for IgAN, offering new hope for patients.

This presentation will explore the latest developments in IgAN clinical trials, highlighting innovative therapies such as targeted-release budesonide and sparsentan, which have demonstrated efficacy in reducing proteinuria and preserving kidney function. Emerging therapies targeting the complement pathway and other novel mechanisms will also be discussed, emphasizing their potential to modify disease progression.

Additionally, the presentation will underscore the importance of patient-centered approaches, addressing the need for individualized treatment strategies, long-term safety and efficacy monitoring, and patient-reported outcomes. By reviewing these advancements, the speech aims to provide a comprehensive overview of how clinical trials are paving the way for a more promising future in the treatment of IgA nephropathy.

